Effect of Elvitegravir,Cobicistat,Emtricitabine and Tenofovir Alafenamide single tablet alone and TDF+3TC+EFV scheme in the treatment of AIDS based on single blind prospective randomized trials
10.3969/j.issn.1673-4130.2024.01.005
- VernacularTitle:基于单盲前瞻性随机试验探讨艾考恩丙替片单药与TDF+3TC+EFV方案治疗AIDS的效果比较
- Author:
Xiaoming LIAN
1
;
Jinrong MO
;
Jiong LIAO
;
Ping HUANG
Author Information
1. 来宾市人民医院感染性疾病科,广西来宾 546100
- Keywords:
Elvitegravir,Cobicistat,Emtricitabine and Tenofovir Alafenamide tablet;
lamivudine;
efa-virenz;
tenofovir;
acquired immunodeficiency syndrome
- From:
International Journal of Laboratory Medicine
2024;45(1):22-28
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of Elvitegravir,Cobicistat,Emtricitabine and Tenofovir Alafenamide single tablet alone versus tenofovir(TDF)+lamivudine(3TC)+efavirenz(EFV)scheme in the treatment of patients with acquired immunodeficiency syndrome(AIDS).Methods A total of 100 patients with AIDS who visited the hospital from January 2022 to October 2022 were selected and divided into two groups by random number table method,50 cases in each group.Group A was treated with Elvitegravir,Cobi-cistat,Emtricitabine and Tenofovir Alafenamide single tablet monotherapy and Group B was treated with TDF+3TC+EFV scheme.The human immunodeficiency virus(HIV)load,body immunity(CD4+,CD8+,CD4+CD38+cell ratio,CD8+CD38+cell ratio),lipid metabolism indexes[total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)],glucose metabolism indexes[fasting blood glucose(FPG),glycated hemoglobin(HbA1c)],glycoprotein 130(gp130),interleukin-35(IL-35)and its receptor IL-12Rβ2 levels were observed before and after treatment in the two groups,and the drug safety in the two groups was counted.Results After 3 months of treatment,HIV load,CD8+count,CD4+CD38+cell ratio,and CD8+CD38+cell ratio in both groups were lower than those before treatment,and CD4+count was higher than that before treatment(P＜0.05),but the difference was not statistically significant when compared between A and B groups(P＞0.05).After 3 months of treat-ment,the levels of IL-12Rβ2,gp130,IL-35,TC,TG,and LDL-C in both groups were higher than those before treatment,and HDL-C level was lower than that before treatment,and the change in group B was greater than that in group A(P＜0.05).FPG and HbAlc levels were higher in group B after 1 month and 3 months of treatment,and were higher than those in group A(P＜0.05).Drug safety analysis showed that the incidence rates of adverse reactions were 12.00％(6/50)in group A and 26.00％(13/50)in group B,and there was no statistically significant difference between the two groups(P＞0.05).The incidence rates of liver and kidney injury in group A was 10.00％(5/50),and that in group B was 12.00％(6/50),and there was no statistically significant difference between two groups(P＞0.05).Conclusion Elvitegravir,Cobicistat,Emtricitabine and Tenofovir Alafenamide single tablet monotherapy and the TDF+3TC+EFV scheme could significantly re-duce the HIV load of AIDS patients and improve their immune level,but the former has less effect on pa-tients'glycolipid metabolism and inflammatory factors,and the monotherapy scheme is superior based on the comprehensive consideration of safety and efficacy.
